Besponsa ‘More Effective’ at Driving Remission for Pediatric B-ALL

Apr 24, 2024

Besponsa provides another — and potentially more effective — option outside of traditional chemotherapy for pediatric patients with relapsed or refractory B-ALL.

Comments

A new CAR-T-cell therapy tricks cancer cells with a decoy to increase treatment efficiency in B-cell Acute Lymphoblastic Leukaemia

Experimental treatment borrowed from blood cancer shows promise for pediatric brain tumors

Classifying childhood brain cancers by immune response may improve diagnostics and treatments

Is Less More? Rethinking Salvage Therapy in Pediatric Hodgkin Lymphoma

Newborns with heart defects may face a higher risk of developing childhood cancer

New therapeutic approach shows promise for pediatric high-grade gliomas

Space-age lessons could protect childhood cancer survivors’ bone health

Suicidal ideation significantly higher among childhood cancer survivors

New test identifies high-risk childhood brain tumours, improving treatment decisions

Melanoma risk doubles among childhood cancer survivors

Recent Posts

Besponsa ‘More Effective’ at Driving Remission for Pediatric B-ALL

Comments

A new CAR-T-cell therapy tricks cancer cells with a decoy to increase treatment efficiency in B-cell Acute Lymphoblastic Leukaemia

Experimental treatment borrowed from blood cancer shows promise for pediatric brain tumors

Classifying childhood brain cancers by immune response may improve diagnostics and treatments

Is Less More? Rethinking Salvage Therapy in Pediatric Hodgkin Lymphoma

Newborns with heart defects may face a higher risk of developing childhood cancer

New therapeutic approach shows promise for pediatric high-grade gliomas

Space-age lessons could protect childhood cancer survivors’ bone health

Suicidal ideation significantly higher among childhood cancer survivors

New test identifies high-risk childhood brain tumours, improving treatment decisions

Melanoma risk doubles among childhood cancer survivors

Archive

Search By Tags